Diagnostik und Therapie des Chylomikronämie-Syndroms

Literatur

• 1 Fojo S S, Brewer H B. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C II.  J Intern Medicine. 1992;  231 669-677
• 2 Klör H U. Das Chylomikronämie-Syndrom – Pathophysiologie, Klinik und Therapie.  Klin Wochenschr. 1990;  68 (Suppl 22) 68-75
• 3 Mead J R, Irvine S A, Ramji D P. Lipoprotein lipase: structure, function, regulation, and role in disease.  J Molecular Medicine. 2002;  80 753-769
• 4 Patsch J R, Miesenböck G, Hopferwieser T et al. Relation of triglyzeride metabolism and coronary artery disesase. Studies in the postprandial state.  Arterioscler Thromb. 1992;  12 1336-1345
• 5 Fruchart J C, Nierman M C, Stroes E S et al. New risk factors for atherosclerosis and patient risk assessment.  Circulation. 2004;  109 (Suppl 1) III15-III19
• 6 Fischer S, Hanefeld M, Müller-Wieland D et al. Fachkommission Diabetes et al. Praxis-Leitlinien für Diagnostik und Therapie von Fettstoffwechselstörungen. 1. Auflage. Dresden: Institut für Medizinische Informatik und Biometrie der Technischen Universität Dresden 2003
• 7 Kostner G M, Scharnagl H, Kostner K et al. Zusammensetzung und Stoffwechsel der Lipoproteine. In: Schwandt P, Parhofer KG. Handbuch der Fettstoffwechselstörungen 2007
• 8 Beil F U, Fojo S S, Brewer H B et al. Apolipoprotein-C-II deficiency syndrome due to apo C-II-Hamburg: clinical and biochemical features and HphI restriction enzyme polymorphism.  Eur J Clin Invest. 1992;  22 88-95
• 9 Gabelli C, Bilato C, Santamarina-Fojo S et al. Heterozygous apolipoprotein C-II-deficiency: lipoprotein and apoprotein phenotype and Rsal restriction enzyme polymorphism in the Apo-C-II-Padova-kindred.  Eur J Clin Invest. 1993;  23 522-528
• 10 Huttunen J K, Ehnholm C, Kekki M et al. Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlations to sex, age and various parameters of triglyceride metabolism.  Clinical Science and Molecular Medicine. 1976;  50 249-260
• 11 Hayden M R, Kastelein J J, Funke H et al. Phenotypic variation of mutations in the human lipoprotein-lipase gene.  Biochem Soc Trans. 1993;  21 506-509
• 12 Miller J P. Serum triglycerides, the liver and the pancreas.  Curr Opin Lipidol. 2000;  11 377-382
• 13 Yoshimura T, Ito M, Akoda Y et al. Rare case of autoimmune hyperchylomicronemia during pregnancy.  Eur J Obstet Gynecol Reprod Biol. 1998;  76 49-51
• 14 Pruneta V, Moulin P, Labrousse F et al. Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy.  J Clin Endocrinol Metab. 1997;  82 791-796
• 15 Beigneux A P, Weinstein M M, Davies B SJ et al. GPIHBP1 and lipolysis: an update.  Curr Opin Lipidol. 2009;  20 211-216
• 16 Franssen R, Young S G, Peelman F et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects.  Cardiocascular Genetics. 2010;  3 169-178
• 17 Henzen C, Röck M, Schnieper C et al. Heparin und Insulin in der Therapie der akuten hypertriglyzeridämieinduzierten Pankreatitis.  Schweiz Med Wochenschr. 1999;  129 1242-1248
• 18 Goldberg A C, Schonfeld G, Feldman E B et al. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.  Clin Ther. 1989;  11 69-83
• 19 Wechsler J G, Hutt V, Klör H U et al. Bezafibrate in primary hyperlipidemias.  Klin Wochenschr. 1982;  60 97
• 20 Leaf D A, Connor W E, Illingworth R et al. The hypolipidemic effects of Gemfibrozil in type V hyperlipidemia.  JAMA. 1989;  8 3154-3160
• 21 Singer P, Wirth M, Berger I. A possible contribution of decrease in free fatty acids to low serum triglyceride levels after diets supplemented with n-6 and n-3 polyunsaturated fatty acids.  Atherosclerosis. 1990;  83 167-175
• 22 Friedberg C E, Janssen M J, Heine R J et al. Fish oil and glycemic control in diabetes. A meta-analysis.  Diabetes Care. 1998;  21 494-500